Search Results for “New LFCA Test Score Report Free PDF | Valid LFCA Test Questions: Linux Foundation Certified IT Associat 🥅 Search on ⏩ www.pdfvce.com ⏪ for ⇛ LFCA ⇚ to obtain exam materials for free download 🌱LFCA Vce Exam” – Page 11

Clinically relevant outcome measures for assessing disease activity, disease control and quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedema

99.	Weller, K., Zuberbier, T., and Maurer, M.: Clinically relevant outcome measures for assessing disease activity, disease control and quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedema. Curr. Opin. Allergy Clin. Immunol. 2015: 15; 220-226. IF: 2.77

r.099

31.	Hakim-Rad, K., Metz, M., and Maurer, M.: Mast Cells: Makers and Breakers of allergic inflammation. Curr. Opin. Allergy Clin. Immunol. 2009: 9; 427-430. IF: 3.15

385.	Kulthanan, K., Ungprasert, P., Tuchinda, P., Chularojanamontri, L., Charoenpipatsin, N., and Maurer, M.⁺: Delayed pressure urticaria: a systematic review of treatment options. J. Allergy Clin. Immunol. Pract. 2020: 8; 2035-2049. IF: 8.86

o.385

Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America

347

Cherrez-Ojeda, I.+, Maurer, M., Bernstein, J. A., Vanegas, E., Felix, M., Ramon, G. D., Ensina, L. F., Larco Sousa, J. I., Matos Benavides, E. E., Cardona Villa, R., Latour Staffeld, P., Morfin-Maciel, B. M., Mori, J., Wilches, P. C.; Mata, V. L., and Cherrez, A.: Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America. World Allergy Organ. J. 2019: 12; 100011. IF: TBD (IF 2018: 3.68)

o.347

131	Magerl, M., Pisarevskaja, D., Staubach, P., Martus, P., Church, M. K.+, and Maurer, M.: Critical temperature threshold measurement for cold urticaria: a randomised controlled trial of H1-antihistamine up-dosing. Brit. J. Dermatol. 2012: 166; 1095-1099. IF: 3.75

o.131

262	Weller, K.+, Magerl, M., Peveling-Oberhag, A., Martus, P., Staubach, P., and Maurer, M.: The angioedema quality of life questionnaire (AE-QoL) – assessment of sensitivity to change and minimal clinically important difference. Allergy 2016: 71; 1203-1209. IF: 7.36

102.	Kolkhir, P., Pogorelow, D., Olisova, O., and Maurer, M.+: Comorbidity and pathogenic links of chronic spontaneous urticaria and systemic lupus erythematosus – a systemic review. Clin. Exp. Allergy 2016: 46; 275-287. IF: 5.26

Action protectrice des éthers phénoliques au course de l’intoxication histaminique (Protective action of phenolic ethers on the course of histamine intoxication) D Bovet and Mlle A-M Staub (20)

23.

Church, M. K. and Maurer M.: Action protectrice des éthers phénoliques au course de l’intoxication histaminique (Protective action of phenolic ethers on the course of histamine intoxication) D Bovet and Mlle A-M Staub (20). In: Sheikh, A., Platts-Mills, T., and Worth, A., editors: Landmarks in Allergy Seminal Papers in Allergy with Expert Commentaries. Oxford: University Press, 2013

43	Staubach, P., Eckhardt-Henn, A., Dechene, M., Hanau, A., Metz, M., Magerl, M., Breuer, P., and Maurer, M.+: Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Brit. J. Dermatol. 2006: 154; 294-298. IF: 3.33

108.	Rietzler, M., Maurer, M., Siebenhaar, F., Angelino, S, Handt, J., Burghardt, R., and Smetana, H.: Innovative approaches to avoid electric shaving-induced skin irritation. Int. J. Cosmet. Sci. 2016: 38; Suppl. 1; 10-16. IF: 1.58

r.108

Results